Checkpoint Therapeutics Inc. (NASDAQ: CKPT)
$2.67
+0.1550 ( +6.17% ) 621.4K
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in theĀ USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.